Automate Your Wheel Strategy on RMD
With Tiblio's Option Bot, you can configure your own wheel strategy including RMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RMD
- Rev/Share 35.8935
- Book/Share 41.7914
- PB 6.0412
- Debt/Equity 0.1383
- CurrentRatio 2.8879
- ROIC 0.1962
- MktCap 36998905141.0
- FreeCF/Share 12.0648
- PFCF 20.937
- PE 25.7178
- Debt/Assets 0.1019
- DivYield 0.009
- ROE 0.2513
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RMD | Robert W. Baird | Outperform | Neutral | -- | $275 | Dec. 16, 2025 |
| Initiation | RMD | Citigroup | -- | Buy | -- | $330 | Sept. 18, 2025 |
| Upgrade | RMD | CLSA | Hold | Outperform | -- | -- | Sept. 2, 2025 |
| Upgrade | RMD | RBC Capital Mkts | Sector Perform | Outperform | -- | $294 | July 15, 2025 |
| Initiation | RMD | Morgan Stanley | -- | Overweight | -- | -- | March 19, 2025 |
| Initiation | RMD | Goldman | -- | Buy | -- | -- | Jan. 16, 2025 |
| Initiation | RMD | Piper Sandler | -- | Neutral | -- | $252 | Jan. 10, 2025 |
| Initiation | RMD | Stifel | -- | Hold | -- | $250 | Dec. 13, 2024 |
| Initiation | RMD | Robert W. Baird | -- | Outperform | -- | $280 | Sept. 24, 2024 |
| Downgrade | RMD | Wolfe Research | Peer Perform | Underperform | -- | $180 | Sept. 18, 2024 |
News
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is This the Right Time to Add Resmed Stock to Your Portfolio?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Neutral
RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could weigh on future performance.
Read More
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Buy These 5 Low-Leverage Stocks Amid a Reversal of Santa Claus Rally
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
A stalled Santa Claus rally has investors rotating to stability, spotlighting low-leverage names like Resmed that may hold up better amid tech-led volatility.
Read More
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
Read More
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Should You Continue to Hold RMD Stock in Your Portfolio?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.
Read More
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
Published: November 24, 2025 by: Forbes
Sentiment: Neutral
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.
Read More
ResMed: Safe Bet For A Recession Environment
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and significant cash reserves position it favorably for investors who want to protect their portfolio for a recession. RMD's operational efficiency and cash balance support continued dividend growth and potential buybacks.
Read More
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.
Read More
These Analysts Revise Their Forecasts On ResMed Following Q1 Results
Published: October 31, 2025 by: Benzinga
Sentiment: Positive
ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.
Read More
5 Low-Leverage Stocks to Buy as Market Takes a Tumble
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
As markets tumble, low-leverage stocks like RMD, SAFRY, PNR, CASY, and DRS offer safer investment options for steady returns.
Read More
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, RMD, VRT and NFG are some such stocks.
Read More
ResMed Inc. (RMD) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Neutral
ResMed Inc. (NYSE:RMD ) Bank of America Global Healthcare Conference 2025 September 23, 2025 8:20 AM EDT Company Participants Michael Farrell - CEO & Chairman Carlos Nunez - Chief Medical Officer Conference Call Participants Lyanne Harrison - BofA Securities, Research Division Presentation Lyanne Harrison BofA Securities, Research Division Good afternoon, everybody. My name is Lyanne Harrison.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Negative
RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of factors, including an aging population and increasing body mass index (BMI). The study estimates that by 2050, OSA will affect nearly 77 million U.S. adults, representing a relative1 increase of nearly 35% from 2020 and impacting …
Read More
ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
For my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business acquisitions and FDA approvals, proven demand momentum so far, and revenue diversification along with strong profit margins in its peer group. RMD is a proven dividend grower over 10 years while also having an attractive balance sheet risk profile with a low D/E ratio.
Read More
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Top 50 High-Quality Dividend Stocks For August 2025
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flow growth, attractive valuations, and double-digit return estimates.
Read More
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings
Published: August 01, 2025 by: Benzinga
Sentiment: Positive
Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday.
Read More
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.
Read More
About ResMed Inc. (RMD)
- IPO Date 1995-06-02
- Website https://www.resmed.com
- Industry Medical - Instruments & Supplies
- CEO Michael J. Farrell
- Employees 9980